These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 15534010)

  • 21. What explains the diffusion of treatments for mental illness?
    Drake R; Skinner J; Goldman HH
    Am J Psychiatry; 2008 Nov; 165(11):1385-92. PubMed ID: 18981070
    [No Abstract]   [Full Text] [Related]  

  • 22. [Psychopharmacological regulations. Results and commentary to the report on drug regulations 2002].
    Fritze J
    Nervenarzt; 2003 Mar; 74(3):301-6. PubMed ID: 12722759
    [No Abstract]   [Full Text] [Related]  

  • 23. Prescription drug costs for Medicare beneficiaries: coverage and health status matter.
    Stuart B; Shea D; Briesacher B
    Issue Brief (Commonw Fund); 2000 Jan; (365):1-9. PubMed ID: 11584831
    [No Abstract]   [Full Text] [Related]  

  • 24. Finance issue brief: mandated benefits: off-label drug coverage requirements: year end report-2003.
    Plaza CI
    Issue Brief Health Policy Track Serv; 2003 Dec; ():1-9. PubMed ID: 14870745
    [No Abstract]   [Full Text] [Related]  

  • 25. Health insurance oversight issue brief: mandated benefits: off-label drug coverage requirements: year end report--2004.
    Plaza CI
    Issue Brief Health Policy Track Serv; 2004 Dec; ():1-9. PubMed ID: 15726733
    [No Abstract]   [Full Text] [Related]  

  • 26. Do guidelines recommending pharmacogenetic testing of psychiatric patients affect treatment costs and the use of healthcare services?
    Herbild L; Bech M; Gyrd-Hansen D; Christensen M; Werge T; Nielsen KA
    Scand J Public Health; 2011 Mar; 39(2):147-55. PubMed ID: 21257648
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Do drug formulary policies reflect evidence of value?
    Neumann PJ; Lin PJ; Greenberg D; Berger M; Teutsch S; Mansley E; Weinstein MC; Rosen AB
    Am J Manag Care; 2006 Jan; 12(1):30-6. PubMed ID: 16402886
    [TBL] [Abstract][Full Text] [Related]  

  • 28. British Columbia poised to reduce drug coverage.
    Quandt T
    Can HIV AIDS Policy Law Rev; 2002 Mar; 6(3):38-9. PubMed ID: 14979239
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The ethics of 'fail first': guidelines and practical scenarios for step therapy coverage policies.
    Nayak RK; Pearson SD
    Health Aff (Millwood); 2014 Oct; 33(10):1779-85. PubMed ID: 25288422
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral oncolytics: Part 2--legislation targeting cost & access, and other initiatives to reduce costs.
    Mancini R; McBride A; Kruczynski M
    Oncology (Williston Park); 2013 Sep; 27(9):865-6, 871. PubMed ID: 24282981
    [No Abstract]   [Full Text] [Related]  

  • 31. Continuing policy issues in Medicare prescription drug coverage.
    Cubanski J
    Issue Brief (Commonw Fund); 2004 Nov; (710):1-5. PubMed ID: 15597515
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Datapoints: psychotropic medication costs among youth with private insurance in 1998.
    Stein BD; Sturm R; Kapur K; Ringel J
    Psychiatr Serv; 2001 Feb; 52(2):152. PubMed ID: 11157108
    [No Abstract]   [Full Text] [Related]  

  • 33. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
    Goedken AM; Urmie JM; Farris KB; Doucette WR
    Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Controlling pharmacy costs in the NC Medicaid program.
    Dobson LA
    N C Med J; 2003; 64(6):280-2. PubMed ID: 14983617
    [No Abstract]   [Full Text] [Related]  

  • 35. Medicaid program; prescription drugs. Final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2007 Jul; 72(136):39141-245. PubMed ID: 17674494
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug reimbursement policies in Canada--need for improved access to critical therapies.
    LeLorier J; Bell A; Bougher DJ; Cox JL; Turpie AG
    Ann Pharmacother; 2008 Jun; 42(6):869-73. PubMed ID: 18477735
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report.
    Garrison LP; Neumann PJ; Erickson P; Marshall D; Mullins CD
    Value Health; 2007; 10(5):326-35. PubMed ID: 17888097
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Designed delays versus rigorous pragmatic trials: lower carat gold standards can produce relevant drug evaluations.
    Maclure M; Carleton B; Schneeweiss S
    Med Care; 2007 Oct; 45(10 Supl 2):S44-9. PubMed ID: 17909382
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Physician stewardship of health care in an era of finite resources.
    Reuben DB; Cassel CK
    JAMA; 2011 Jul; 306(4):430-1. PubMed ID: 21791692
    [No Abstract]   [Full Text] [Related]  

  • 40. A therapeutic substitution policy for proton pump inhibitors: clinical and economic consequences.
    Schneeweiss S; Maclure M; Dormuth CR; Glynn RJ; Canning C; Avorn J
    Clin Pharmacol Ther; 2006 Apr; 79(4):379-88. PubMed ID: 16580906
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.